KeyBank National Association
AQST icon

KeyBank National Association’s Aquestive Therapeutics AQST Stock Holding History

KeyBank National Association’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,644
Closed -$239K – 938
2018
Q3 		$239K Buy
+13,644
New +$225K ﹤0.01% 958

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KeyBank National Association's AQST Position: Q4 2018 in Review

KeyBank National Association sold out of Aquestive Therapeutics (AQST) in Q4 2018, closing a stake of 13,644 shares — an estimated $239K sold.

KeyBank National Association first reported a position in AQST in Q3 2018 and held it in 1 quarter. The position peaked at $239K in Q3 2018. 36 funds tracked by Wall St. Rank hold AQST as of Q4 2018.

  • KeyBank National Association reported no remaining Aquestive Therapeutics position as of Q4 2018 after selling out during the quarter.
  • KeyBank National Association sold 13,644 Aquestive Therapeutics shares in Q4 2018, an estimated $239K.
  • KeyBank National Association first reported a position in Aquestive Therapeutics in Q3 2018 and held it in 1 quarter.
  • KeyBank National Association's Aquestive Therapeutics position peaked at $239K in Q3 2018.
  • 36 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2018.

Based on KeyBank National Association's 13F filing for Q4 2018, filed 30 Jan 2019.